Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Factors influencing uptake of HPV vaccination among girls in Germany.

Schülein S, Taylor KJ, König J, Claus M, Blettner M, Klug SJ.

BMC Public Health. 2016 Sep 20;16:995. doi: 10.1186/s12889-016-3663-z.

2.

Evaluation of the cost of cervical cancer at the National Institute of Oncology, Rabat.

Cheikh A, El Majjaoui S, Ismaili N, Cheikh Z, Bouajaj J, Nejjari C, El Hassani A, Cherrah Y, Benjaafar N.

Pan Afr Med J. 2016 Apr 20;23:209. doi: 10.11604/pamj.2016.23.209.7750.

3.

Summary and Recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) Workshop "Gonorrhea Vaccines: the Way Forward".

Wetzler LM, Feavers IM, Gray-Owen SD, Jerse AE, Rice PA, Deal CD.

Clin Vaccine Immunol. 2016 Aug 5;23(8):656-63. doi: 10.1128/CVI.00230-16. Review.

4.

Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines.

Burger EA, Lee K, Saraiya M, Thompson TD, Chesson HW, Markowitz LE, Kim JJ.

Cancer. 2016 Jul 1;122(13):2057-66. doi: 10.1002/cncr.30007.

PMID:
27124396
5.

National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States.

Durham DP, Ndeffo-Mbah ML, Skrip LA, Jones FK, Bauch CT, Galvani AP.

Proc Natl Acad Sci U S A. 2016 May 3;113(18):5107-12. doi: 10.1073/pnas.1515528113.

6.

Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China.

Liu YJ, Zhang Q, Hu SY, Zhao FH.

BMC Cancer. 2016 Feb 26;16:164. doi: 10.1186/s12885-016-2207-3.

7.

The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.

Chesson HW, Markowitz LE, Hariri S, Ekwueme DU, Saraiya M.

Hum Vaccin Immunother. 2016 Jun 2;12(6):1363-72. doi: 10.1080/21645515.2016.1140288.

8.

Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.

Ultsch B, Damm O, Beutels P, Bilcke J, Brüggenjürgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, von Kries R, Kuhlmann A, Levy-Bruhl D, Perleth M, Postma M, Salo H, Siebert U, Wasem J, Wichmann O.

Pharmacoeconomics. 2016 Mar;34(3):227-44. doi: 10.1007/s40273-015-0335-2.

9.

Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?

Bonanni P, Gabutti G, Demarteau N, Boccalini S, La Torre G.

BMC Infect Dis. 2015 Sep 17;15:377. doi: 10.1186/s12879-015-1067-9.

10.

Geospatial patterns of human papillomavirus vaccine uptake in Minnesota.

Nelson EJ, Hughes J, Oakes JM, Pankow JS, Kulasingam SL.

BMJ Open. 2015 Aug 27;5(8):e008617. doi: 10.1136/bmjopen-2015-008617.

11.

Cost-effectiveness of Chlamydia vaccination programs for young women.

Owusu-Edusei K Jr, Chesson HW, Gift TL, Brunham RC, Bolan G.

Emerg Infect Dis. 2015 Jun;21(6):960-8. doi: 10.3201/eid2106.141270.

12.

Evaluating Cost-effectiveness of Interventions That Affect Fertility and Childbearing: How Health Effects Are Measured Matters.

Goldhaber-Fiebert JD, Brandeau ML.

Med Decis Making. 2015 Oct;35(7):818-46. doi: 10.1177/0272989X15583845. Review.

13.

Applying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran.

Khatibi M, Rasekh HR.

Iran J Pharm Res. 2015 Spring;14(2):635-49.

14.

Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.

Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group..

Clin Vaccine Immunol. 2015 Apr;22(4):361-73. doi: 10.1128/CVI.00591-14.

15.

Cost-effectiveness of strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in an intensive care unit.

Gidengil CA, Gay C, Huang SS, Platt R, Yokoe D, Lee GM.

Infect Control Hosp Epidemiol. 2015 Jan;36(1):17-27. doi: 10.1017/ice.2014.12.

16.

Systematic review of the cost-effectiveness of the vaccination against HPV in Brazil.

Fonseca AJ, de Lima Ferreira LC.

Hum Vaccin Immunother. 2014;10(12):3484-90. doi: 10.4161/hv.34410. Review.

17.

HPV Vaccine Awareness, Barriers, Intentions, and Uptake in Latina Women.

Lechuga J, Vera-Cala L, Martinez-Donate A.

J Immigr Minor Health. 2016 Feb;18(1):173-8. doi: 10.1007/s10903-014-0139-z.

18.

An updated natural history model of cervical cancer: derivation of model parameters.

Campos NG, Burger EA, Sy S, Sharma M, Schiffman M, Rodriguez AC, Hildesheim A, Herrero R, Kim JJ.

Am J Epidemiol. 2014 Sep 1;180(5):545-55. doi: 10.1093/aje/kwu159.

19.

Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway.

Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ.

J Infect Dis. 2015 Jan 15;211(2):206-15. doi: 10.1093/infdis/jiu413.

20.

Cross-cultural differences and sexual risk behavior of emerging adults.

Thomas TL, Yarandi HN, Dalmida SG, Frados A, Klienert K.

J Transcult Nurs. 2015 Jan;26(1):64-72. doi: 10.1177/1043659614524791.

Items per page

Supplemental Content

Support Center